Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial.
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
19 04 2023
19 04 2023
Historique:
medline:
21
4
2023
pubmed:
19
4
2023
entrez:
19
04
2023
Statut:
ppublish
Résumé
The best assay or marker to define mRNA-1273 vaccine-induced antibodies as a correlate of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA-1273 COVID-19 vaccine or placebo. We previously assessed IgG binding antibodies to the spike protein (spike IgG) or receptor binding domain (RBD IgG) and pseudovirus neutralizing antibody 50 or 80% inhibitory dilution titer measured on day 29 or day 57, as correlates of risk (CoRs) and CoPs against symptomatic COVID-19 over 4 months after dose. Here, we assessed a new marker, live virus 50% microneutralization titer (LV-MN
Identifiants
pubmed: 37075127
doi: 10.1126/scitranslmed.ade9078
pmc: PMC10243212
mid: NIHMS1899084
doi:
Substances chimiques
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
Antibodies, Neutralizing
0
Immunoglobulin G
0
Antibodies, Viral
0
Banques de données
ClinicalTrials.gov
['NCT04470427']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
eade9078Subventions
Organisme : NIH HHS
ID : S10 OD028685
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148685
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068614
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI054165
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148684
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068635
Pays : United States
Références
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Stat Med. 2018 Dec 20;37(29):4374-4385
pubmed: 30091264
Nat Med. 2021 Sep;27(9):1493-1494
pubmed: 34518674
Clin Infect Dis. 2012 Jun;54(11):1615-7
pubmed: 22437237
Nat Med. 2022 Apr;28(4):823-830
pubmed: 35145311
Nat Med. 2021 Jul;27(7):1147-1148
pubmed: 34239135
Stat Appl Genet Mol Biol. 2007;6:Article25
pubmed: 17910531
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Biostatistics. 2022 Jul 15;:
pubmed: 35848843
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Vaccine. 2021 May 12;39(20):2791-2799
pubmed: 33707061
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Electron J Stat. 2015;9(1):1583-1607
pubmed: 26279737
Nat Microbiol. 2022 Dec;7(12):1996-2010
pubmed: 36357712
Vaccine. 2007 May 10;25(19):3816-26
pubmed: 17368878
Biometrics. 2022 May 8;:
pubmed: 35526218
Nat Commun. 2023 Jan 19;14(1):331
pubmed: 36658109
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
N Engl J Med. 2021 Nov 4;385(19):1774-1785
pubmed: 34551225
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Sci Rep. 2021 Dec 14;11(1):23921
pubmed: 34907214
N Engl J Med. 2021 Mar 18;384(11):1003-1014
pubmed: 33730454
J Infect Dis. 2007 Nov 1;196(9):1304-12
pubmed: 17922394